109 related articles for article (PubMed ID: 10704105)
1. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium.
Koeplinger KA; Raub TJ; Padbury GE; Zhao Z
J Pharm Biomed Anal; 1999 Mar; 19(3-4):399-411. PubMed ID: 10704105
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.
Poppe SM; Slade DE; Chong KT; Hinshaw RR; Pagano PJ; Markowitz M; Ho DD; Mo H; Gorman RR; Dueweke TJ; Thaisrivongs S; Tarpley WG
Antimicrob Agents Chemother; 1997 May; 41(5):1058-63. PubMed ID: 9145869
[TBL] [Abstract][Full Text] [Related]
3. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
4. Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
Harris M; Alexander C; O'Shaughnessy M; Montaner JS
AIDS; 2002 Mar; 16(5):798-9. PubMed ID: 11964540
[No Abstract] [Full Text] [Related]
5. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
Periclou AP; Nandy P; Avramis VI
In Vivo; 2000; 14(3):377-88. PubMed ID: 10904870
[TBL] [Abstract][Full Text] [Related]
6. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha.
Pagano PJ; Chong KT
J Infect Dis; 1995 Jan; 171(1):61-7. PubMed ID: 7528253
[TBL] [Abstract][Full Text] [Related]
8. Delavirdine/protease inhibitor interactions.
Gilden D
GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
[TBL] [Abstract][Full Text] [Related]
9. Delaviridine and AZT combination tested in women.
AIDS Patient Care STDS; 1997 Aug; 11(4):288. PubMed ID: 11361846
[No Abstract] [Full Text] [Related]
10. Species-dependent enantioselective pharmacokinetics of PNU-103017, a pyrone HIV protease inhibitor.
Zhong WZ; Williams MG; Borin MT; Padbury GE
Chirality; 1998; 10(3):210-6. PubMed ID: 9499572
[TBL] [Abstract][Full Text] [Related]
11. Delavirdine: clinical pharmacokinetics and drug interactions.
Tran JQ; Gerber JG; Kerr BM
Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
[TBL] [Abstract][Full Text] [Related]
12. Long-term pharmacokinetics of amprenavir in combination with delavirdine in HIV-infected children.
Engelhorn C; Hoffmann F; Kurowski M; Stocker H; Kruse G; Notheis G; Belohradsky BH; Wintergerst U
AIDS; 2004 Jul; 18(10):1473-5. PubMed ID: 15199327
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
[TBL] [Abstract][Full Text] [Related]
14. Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine.
Vuong le T; Ruckle JL; Blood AB; Reid MJ; Wasnich RD; Synal HA; Dueker SR
J Pharm Sci; 2008 Jul; 97(7):2833-43. PubMed ID: 17854048
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro.
Giacca M; Borella S; Calderazzo F; Bianchi LC; D'Agaro P; Rampazzo C; Bianchi V; Reichard P
AIDS Res Hum Retroviruses; 1996 May; 12(8):677-82. PubMed ID: 8744578
[TBL] [Abstract][Full Text] [Related]
16. Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.
Bilello JA; Bilello PA; Stellrecht K; Leonard J; Norbeck DW; Kempf DJ; Robins T; Drusano GL
Antimicrob Agents Chemother; 1996 Jun; 40(6):1491-7. PubMed ID: 8726025
[TBL] [Abstract][Full Text] [Related]
17. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro.
Macchi B; Faraoni I; Zhang J; Grelli S; Favalli C; Mastino A; Bonmassar E
J Gen Virol; 1997 May; 78 ( Pt 5)():1007-16. PubMed ID: 9152417
[TBL] [Abstract][Full Text] [Related]
18. 3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes.
Purcet S; Minuesa G; Molina-Arcas M; Erkizia I; Casado FJ; Clotet B; Martinez-Picado J; Pastor-Anglada M
Antivir Ther; 2006; 11(6):803-11. PubMed ID: 17310825
[TBL] [Abstract][Full Text] [Related]
19. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Wintergerst U; Engelhorn C; Kurowski M; Hoffmann F; Notheis G; Belohradsky BH
AIDS; 2000 Aug; 14(12):1866-8. PubMed ID: 10985332
[No Abstract] [Full Text] [Related]
[Next] [New Search]
